Prognica Labs

Accelerating the Path from
Molecule to Medicine

Making drug discovery
10x faster, 10x cheaper, and infinitely smarter

10× Faster Discovery
AI agents automate data mining, hypothesis generation, and in-silico validation, reducing R&D cycles from months to weeks.

70% Lower Early-Stage Costs
Autonomous evaluation and virtual trials eliminate redundant lab work and due diligence overhead.

50% Reduction in Clinical Risk
Digital twin simulations predict feasibility and operational challenges before execution.

Data-Driven Decision Making
Integrated intelligence stack offers real-time insights across discovery, safety, and market analytics.

De-Risked Investment Pathways
Business development agents map exit strategies and acquirer fit early in the pipeline.

Accelerated Market Entry
Commercial intelligence models prioritize assets with high unmet need and payer readiness.

Products & Technology

Our core AI Platforms

End‑to‑end stack of AI agents and human expert review to discover, evaluate, de‑risk, develop (to early clinical stages) and commercialize overlooked or abandoned drug assets.

Asset Discovery Agent

Autonomous AI for Intelligent Drug Asset Mining and Evaluation

Autonomous scraping/mining of public and private data (papers, patents, preclinical literature, databases) to surface overlooked candidates and abandoned IP with potential translational fit.

In-Silico Evaluation Suite

Computational Biology Platform for Mechanistic Insight and Safety Prediction

An AI-driven computational biology platform that simulates and evaluates drug behavior before it enters the lab. Designed to accelerate preclinical decision-making, it integrates molecular modeling, dynamics simulations, pharmaco-kinetic estimation, and safety profiling, allowing researchers to assess mechanistic plausibility, efficacy potential, and toxicity risk entirely in silico.

Market & Commercial Insight

Market Validation, Asset Prioritization, and Commercial Strategy

An AI-driven analytics engine that bridges scientific discovery with commercial reality. Designed to evaluate the true market potential of drug assets, it integrates predictive modeling, real-world data, and economic intelligence to estimate unmet need, addressable market, payer sentiment, and reimbursement feasibility.

Business Development Agent

AI-Powered Deal Intelligence for Asset Commercialization and Strategic Partnering

An AI-driven platform for deal intelligence, strategic positioning, and exit enablement in pharmaceutical asset transactions. Designed to bridge the gap between scientific discovery and market realization, it autonomously generates investor-ready materials, deal structures, and partnership frameworks aligned to each asset’s modality, stage, and market trajectory.

Clinical Operations Agent

Digital Twin Simulations for Clinical Feasibility, Risk Forecasting, and Trial Optimization

The Clinical Operations / Digital Twin Agent an intelligent simulation platform designed to digitally replicate every critical dimension of a clinical trial – from protocol design to operational execution. Using AI-powered digital twin modeling, it predicts feasibility, identifies risk points, and optimizes trial parameters before the first patient is enrolled.

Research & Publications

Evidence based approach

Building scientific evidence is foundational to the responsible and effective development of AI systems, especially in fields like life sciences, healthcare, and biotechnology, where evidence-based practices are paramount. Our AI-based solutions empowering patients, are built on scientific evidence transforms AI from a mere technology to a trusted partner in human health and research.